TCR2 Therapeutics Inc. Common Stock
TCRR
TCRR was delisted on the 31st of May, 2023.
117 hedge funds and large institutions have $270M invested in TCR2 Therapeutics Inc. Common Stock in 2021 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 41 increasing their positions, 35 reducing their positions, and 20 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 35
2% less funds holding
Funds holding: 119 → 117 (-2)
10% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 20
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
53% less capital invested
Capital invested by funds: $572M → $270M (-$301M)
69% less call options, than puts
Call options by funds: $1.3M | Put options by funds: $4.14M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$8.21M |
| 2 |
MWNA
Marshall Wace North America
New York
|
+$7.68M |
| 3 |
GTC
Ghost Tree Capital
New York
|
+$6.74M |
| 4 |
JP Morgan Chase
New York
|
+$5.24M |
| 5 |
Millennium Management
New York
|
+$3.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$36.6M |
| 2 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$15.3M |
| 3 |
State Street
Boston,
Massachusetts
|
-$10.1M |
| 4 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$4.86M |
| 5 |
RCAMU
Rothschild & Co Asset Management US
Stamford,
Connecticut
|
-$4.83M |
TCRR Hedge Fund Activity: Q3 2021 in Review
117 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q3 2021, worth a combined $270M — down 53% from $572M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of TCRR and 18 opened new positions — a net loss of 2 holders — while 35 trimmed existing stakes and 41 added.
The largest buyer was Redmile Group, adding an estimated $8.21M. The largest seller was Wellington Management Group, cutting an estimated $36.6M.
- 117 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q3 2021, down from 119 in Q2 2021.
- Funds reported $270M of TCR2 Therapeutics Inc. Common Stock stock for Q3 2021, down 53% quarter-over-quarter.
- 18 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q3 2021 and 20 closed out, a net change of -2 holders.
- The largest TCR2 Therapeutics Inc. Common Stock buyer in Q3 2021 was Redmile Group, an estimated $8.21M added.
- The largest TCR2 Therapeutics Inc. Common Stock seller in Q3 2021 was Wellington Management Group, an estimated $36.6M sold.
Based on aggregated 13F filings for Q3 2021.